| Company/Division name | Emergent BioSolutions |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2024 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 250 |
| City reshored to: | Rockville |
| State(s) reshored to: | MD |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | medical countermeasures (smallpox vaccines, etc) |
| What domestic positive factors made reshoring more attractive? | Government Incentives, Impact on domestic economy |
| Government Incentive dollar amount: | DoD contracts |
